Plasma 5-hydroxytryptamine (serotonin), tryptophan and neopterin levels were measured in patients with depressive cancer cachexia and in healthy controls during the same time period. Patients with advanced cancers had significantly raised neopterin, a marker of endogenous gamma-interferon (IFN-y) production, but decreased serotonin and tryptophan levels. IFN-y induces a high level of indoleamine dioxvgenase (IDa), a tryptophan degrading enzyme, which in turn increases metabolism along the tryptophan-nicotinic acid pathway, resulting in decreased synthesis of serotonin. These results suggest that persistent immune activation occur in patients with cancer cachexia, resulting in disorders involving tryptophan metabolism .
Introduction
Infection, lipopolysaccharide administration, or interferon treatment results in the induction of an enzyme, indole amine 2,3-dioxygenase (100), in a variety of nonhepatic tissues ( 1) . This enzyme is distinct from the liver tryptophan dioxygenase enzyme in its tissue distribution, molecular weight, immunogenicity, requirement for superoxide anion and inducibility. Like the liver enzyme, it results in conversion of L-tryptophan to formylkynurenine and subsequent metabolites of this pathway. Earlier studies reported that human recombinant interferon-gamma (IFN-y) induced tryptophan degradation in vitro in human cell cultures and in vivo in patients from phase I clinical trial (2) . This increase in tryptophan catabolism is § Author to whom correspondence should be addressed.
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undoubtedly the result of the induction of 100. 100 is an extrahepatic enzyme, distinct from liver tryptophan dioxygenase, which opens the indole ring of tryptophan, and to a lesser extent of serotonin and certain other indoles, using the superoxide anion as a required oxygen source (3). Production and excretion of neopterin (Fig. I) , a metabolite of guanosine triphosphate (GTP), is also increased in some patients by allogeneic immune stimulation and by IFN-y (4). This increase in neopterin results from induction of GTP cyclohydrolase, which initiates neopterin synthesis in macrophages . The present study was done to assess the relationship between neopterin and tryptophan metabolism in cancer patients representing cachexia and to evaluate the utility of tryptophan and neopterin measurements as indices of cancerburden states. Figure 1 . The interaction of T-cell and macrophages. Ncoptcrin ( NPT ), a ptcridine intermediate metabolite in the biopterine synthetic pathway, is synthesized and secreted by monocyre/macrophages upon stimulation, mainly by gamma-interferon produced by activated T cells. NFT is biologically stable and is not metabolized and, theret(xe , the measurement of NPT can be considered an indirect evaluation of e ndogenous gamma-interferon production.
Materials and Methods
28 to 88 years, with a median age of 58 years, suffering from gastrointestinal cancers were used as subjects in this study. Patients were serologically and/or histologically confirmed as having metastasizing and/or recurrent cancers. These cancers were unrcscctablc and noncurable malignant solid tumors. All patients had cachectic symptoms, such as body weight loss, appetite loss, anemia, pain and/or depressive states . Venous blood samples were collected at 8:00 a.m. and no patient was undergoing concomitant therapy with steroids and/or other drugs which may affect the immune system. Serum neopterin, tryptophan and serotonin were measured in these patients and in a group of healthy controls during the same time period. Plasma neopterin concentrations were measured by high pressure liquid chromatography (HPLC). Plasma tryptophan and serotonin levels were measured by an aminoacids autoanalyzer (Hitachi 835-50, Japan) and reversed phase ionpair HPLC, respectively. Data are reported as mean+SE and analyzed by unpaired Student's-t 
Results
Patients with advanced cancers had significantly raised neopterin levels, and significantly decreased tryptophan and serotonin levels in comparison with healthy controls (Table 1) .
Discussions
Earlier studies had reported disturbances of tryptophan metabolism in patients witll. certain autoimmune diseases such as rheumatoid arthritis, scleroderma, Wegner's granulomatosis and cancerburden state (5, 6, 7) . Prior to the discovery of the IDO enzyme, it was believed that some of these tryptophan metabolism abnormalities were the result of stress or hormonal induction of liver tryptophan degradation or due to a functional deficiency of vitamin B-6 causing a block in further kynurenine metabolism (8) . With the discovery of IDO and its induction by IFN-y, and with reports of elevated IFN-y levels in several autoimmune diseases (9) , it now seems most likely that many of the previously reported abnormalities of tryptophan metabolism were the result of IFN-y-induced IDO activity rather than enhanced activity of the liver enzyme (10) .
The present research has demonstrated that patients with advanced cancers had significantly raised neopterin, and significantly decreased tryptophan levels in comparison with healthy controls. A similar study was already published in patients with hematological neoplasias by Denz et al. (7) . They addressed the question of weight loss, the main symptom of so called cancer cachexia, is associated with abnormalities of tryptophan metabolism. Weight loss was seen particularly in patients with higher neopterin levels and lower tryptophan values. An association between higher neopterin levels and greater weight loss was apparent, which support the concept that weight loss is closely linked to endogenous IFN-y activity.
I t remains uncertain whether increased concentrations of neopterin in cancer-burden patients are, at least in part, due to the direct effect of endogenous IFN -y induction. Earlier studies reported that large quantities of neopterin were released by human macrophages on stimulation with IFN-y in vitro. Thus, it seems most likely that the induction of IDO and neopterin production are mediated, at least in part, via in-duction of IFN -y. Decreased tryptophan could result from increased activity of IDO which is induced by IFN-y and degrades tryptophan to form kynurenine , which is then further metabolized . Release of neopterin, therefore, is paralleled by a significant degradation of tryptophan. Thus, reduced tryptophan levels very likely result from persistent immune activation through high activities ofIDO.
In view of the essential nature of tryptophan, not only for protein synthesis, but also for synthesis of the neuroimmunomodulator serotonin, it is important to consider the possible physiological and nutritional implications of the marked decrease in plasma tryptophan observed in the present study. Such decreases in tryptophan could readily lead to inhibition of protein synthesis and to low levels of serotonin, potentially causing neurological, vascular and muscular changes . In fact, the serotonin levels in cancer-burden patients were significantly decreased compared with healthy controls. Additionally, serotonin may be involved in the release of pituitary prolactin and growth hormone ( 11) . If the toxic or biological effects of systemically administered IFN-y are, even in part, due to this induced tryptophan det1ciency, then the provision of exogenous tryptophan may potentially ameliorate some of these toxicities. However, if metabolites of tryptophan are responsible for toxicity, especially when IDO levels are increased, then supplementation with tryptophan may enhance toxicity and might not be desirable .
Elevation of neopterin concentrations, which is an indirect marker of endogenous IFN-y production, was detected in a variety of diseases in which immune activation is known to be an actor, such as allograft rejection , virus and microbe infections, causing autoimmune diseases and infection with human immunodeficiency virus type I (HIV-I). In all diseases, T-cell responses in vitro are typically diminished, possibly by the in vivo presence of cytokines due to persistent immune activation. The defective in vitro response of Tcells to soluble antigens was shown to be associated with raised neopterin concentrations in vivo in early stages of HIV -I infection. Recent research has revealed that elevated neopterin concentrations are associated with a subsequent decrease in CD4 + -T cell counts which serves as a strong predictor of the progression of AIDS. Thus, accumulated data on patients with HIV-I infection demonstrate that immune activation with elevated neopterin concentrations may coexist with functional defects of immune effector mechanisms.
At an immunological level, serotonin reduces IFN-y induced expression of HLA-Ia surface antigens on mouse macrophages (12), competes with muramyl peptides for receptor binding and influences immune responses (13) . As described above, serotonin also acts as a growth factor for intestinal mucosal cells, and blockage of serotonin synthesis by inhibition of biopterin synthesis leads to intestinal necrosis in mice which is relieved by administration of tetrahydrobiopterin, the cofactor for hydroxylation of tryptophan ( 14) . The present research demonstrated that plasma serotonin and tryptophan levels were decreased in cancer-burden patients, probably due to increased neopterin concentrations and the relevance of IDO activation (Fig. 2) . These results suggested therapeutic or at least palliative approaches to the management of cancer cachexia, i.e. restoration of tryptophan levels by prevention of tryptophan catabolism by IDO. As described above, in view of reports of the markedly enhanced toxicity of tryptophan in rodents pretreated with LPS and the risk of elevating kynurenin levels, which induces mental and metabolic disorders, simple trials of tryptophan supplementation in humans who may have elevated IDO levels will have to proceed with caution.
